-
BOC/BOA 2024丨New Breakthroughs in ADC Drugs for Breast Cancer Treatment—Professor Ying Fan Interprets the DB-06 and OptiTROP-Breast01 Studies
In the field of breast cancer treatment, the rapid development of antibody-drug conjugates (ADCs) is gradually changing the traditional treatment landscape, bringing more hope to patients. The presentation of the DB-06 and OptiTROP-Breast01 studies at the 2024 ASCO conference has elevated the application of ADC drugs in breast cancer treatment to a new level. At…
-
First Immunotherapy Combined with ADC Neoadjuvant Treatment for MIBC Revealed, Meeting the Survival Needs of More Patients
The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was held from May 31 to June 4 in Chicago, USA, showcasing numerous cutting-edge research findings that will further advance the diagnosis and treatment practices in the field of urological tumors. Among them, a multicenter Phase II clinical study conducted in China, led by Peking…
-
BOC/BOA 2024丨Professor Yu Chen: Exploring New Strategies for Melanoma Treatment and Tackling Immunotherapy Resistance
Melanoma is one of the more common malignant tumors clinically. In recent years, although immunotherapy has brought new hope to melanoma patients, the issue of resistance has become increasingly prominent. At the 2024 Annual Progress Seminar of Chinese Clinical Oncology (BOC) and Beast of ASCO® 2024 China (BOC/BOA 2024), Professor Yu Chen from Fujian Cancer…
-
Professor Pei Dong: Continuously Exploring Individualized Treatment Strategies for Advanced Kidney Cancer in China
Kidney cancer is one of the three major tumors of the urinary system. According to statistics, in 2022, there were approximately 77,000 new cases and 46,000 deaths from kidney cancer in China. The prognosis for advanced metastatic kidney cancer is poor, with a five-year overall survival rate of less than 20% with targeted therapy alone.…
-
Prophylactic Infusion of Donor-Derived CD7 CAR-T Cells Post-Allo-HSCT for Treating R/R T-ALL/LBL
Recent clinical studies have shown that CD7-targeted chimeric antigen receptor T-cell (CAR-T) therapy is effective and safe for patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL). Combining CAR-T therapy with transplantation has the potential to enhance treatment efficacy and reduce disease recurrence. Most existing studies have implemented CD7 CAR-T cells as a bridge to allogeneic hematopoietic…
-
EHA Expert Interview | Three Studies from Professor Sanbin Wang’s Team Selected for EHA: An In-Depth Review
The 29th European Hematology Association (EHA) Annual Congress was held in Madrid, Spain, from June 13 to 16, 2024. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars worldwide to share and discuss innovative ideas and the latest scientific and clinical research achievements in hematology. At this…
-
BOC/BOA 2024丨Professor Xiaojie Bian: Radioligand Therapy & PROTAC Treatment Bring New Hope for mCRPC
From July 5 to 7, 2024, the 2024 Annual Progress Seminar of Chinese Clinical Oncology (BOC) and Beast of ASCO® 2024 China (BOC/BOA) was grandly held in Guangzhou. On the 6th, Professor Xiaojie Bian from Fudan University Shanghai Cancer Center shared the latest drug development progress for metastatic castration-resistant prostate cancer (mCRPC) from the 2024…
-
Embrace the synergy of global expertise and local insights with Professor Zefei Jiang at the 2024 Best of ASCO/Best of CSCO.
As the Vice Chairman and Secretary-General of the Chinese Society of Clinical Oncology (CSCO), he leads the charge in aligning Chinese clinical oncology with international standards. Experience the cutting-edge advancements in targeted therapies, immunotherapies, and the integration of precision medicine. Let’s innovate together for a future where cancer treatment knows no borders.
Connecting Medical Expertise through Media